
Appendix 16c: Forest plots for clinical evidence reviews on psychological vs. pharmacological interventions, combination therapy and other medical interventions

Psychological vs. Pharmacological (OCD); Combination therapy (OCD); Other medical interventions



Review: OCD: psychological v pharmacological Comparison: 01 ERP vs Clomipramine Outcome: 01 Y-BOCS or Compulsion checklist

Study or sub-category	N	ERP Mean (SD)	N	Clomipramine Mean (SD)		SMD (fi 95%			SMD (fixed) 95% Cl
01 ERP v CMI (Y-BOCS)									
Foa 2005	21	11.00(7.90)	27	18.20(7.80)		-		-	0.90 [-1.50, -0.30]
Subtotal (95% CI)	21		27			•		-	0.90 [-1.50, -0.30]
Test for heterogeneity; not a Test for overall effect: $Z = 2$									
02 ERP + placebo v CMI + re	laxation (Compul	sion Checklist at week 7)							
Marks 1980	10	28.00(18.10)	10	31.30(20.50)			_	-	0.16 [-1.04, 0.71]
Subtotal (95% CI)	10		10			-	-	-	0.16 [-1.04, 0.71]
Test for heterogeneity: not a Test for overall effect: Z = 0									
Total (95% CI)	31		37			•		-	-0.67 [-1.16, -0.17]
Test for heterogeneity: Chi ² : Test for overall effect: Z = 2		= 0.17), I² = 46.1%							
					-4	-2 0	2	4	
					F	avours ERP	Favours Clomi	nramine	

Review: OCD: psychological v pharmacological

Comparison: 01 ERP vs Clomipramine
Outcome: 02 Leaving the study early

Study or sub-category	ERP n/N	Clomipramine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Foa 2005	16/37	20/47	-	1.02 [0.62, 1.67]
Total (95% CI) Total events: 16 (ERP), 20 (C Test for heterogeneity: not a Test for overall effect: Z = 0	pplicable	47	+	1.02 [0.62, 1.67]
•		0.1	0.2 0.5 1 2 5	10

Favours ERP

Favours Clomipramine


Review: OCD: psychological v pharmacological


Comparison: 01 ERP vs Clomipramine Outcome: 03 Non-responders (CGI)

Study or sub-category	ERP n/N	Clomipramine n/N	RR (fixed) 95% CI	RR (fixed) 95% Cl
Foa 2005	32/47	19/37	-	1.33 [0.92, 1.92]
Total (95% CI) Total events: 32 (ERP), 19 (Clom Test for heterogeneity: not applio Test for overall effect: Z = 1.50 (applicable	37	•	1.33 [0.92, 1.92]
		0.1	0.2 0.5 1 2 5	10
			Favours ERP Favours Clomip	pramine

Review: OCD: psychological v pharmacological Comparison: 02 Children: CBT v Clomipramine

Outcome: 01 Leaving the study early






Favours CBT Favours Clomipramine


OCD: psychological v pharmacological Review:

03 Children: CBT v Sertraline Comparison: 01 Leaving the study early Outcome:




Review: OCD: psychological v pharmacological 03 Children: CBT v Sertraline Comparison:

02 CY-BOCS



Combination therapy (OCD)

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP Outcome: 01 Leaving the study early



Review: OCD: combination therapy

Comparison: 01 ERP+ SRI v ERP

Outcome: 02 Leaving the study early due to adverse effects

Study or sub-category	ERP+ SRI ERP RR (fixed) n/N n/N 95% CI		RR (fixed) 95% CI		
01 ERP + Fluvoxamine v ERP	+ placebo				
Cottraux 1990	2/20	1/20			2.00 [0.20, 20.33]
Subtotal (95% CI)	2/20	1/20			2.00 [0.20, 20.33]
Test for heterogeneity: not ap	oplicable				
Test for overall effect: Z = 0.	59 (P = 0.56)				
				 	100
		0.0	1 0.1	1 10	100


Favours ERP+SRI Favours ERP

Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP

Outcome: 03 Non-responders (Y-BOCS 35%)

Study BT + SRI ΒТ RR (fixed) RR (fixed) n/Ν 95% CI 95% CI or sub-category n/N 01 MBT + Fluvoxamine v MBT + placebo Hohagen 1998 3/24 10/25 0.31 [0.10, 1.00] Subtotal (95% CI) 3/24 10/25 0.31 [0.10, 1.00] Test for heterogeneity: not applicable Test for overall effect: Z = 1.96 (P = 0.05) 0.01 0.1 10 100 Favours BT+SRI Favours BT

Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: Outcome: 04 Non-responders (CGI)



Review: OCD: combination therapy

Comparison: 01 ERP+ SRI v ERP

Outcome: 06 Global criterion of non-improvement (duration of rituals)

Study or sub-category	ERP + SRI n/N	ERP n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
01 ERP + Fluvoxamine v ERP	+ placebo: post-treatment			
Cottraux 1990	9/20	14/20		0.64 [0.37, 1.13]
Subtotal (95% CI)	9/20	14/20		0.64 [0.37, 1.13]
Test for heterogeneity: not a	pplicable		-	•
Test for overall effect: Z = 1	.54 (P = 0.12)			
02 ERP + Fluvoxamine v ERP	+ placebo: 6 months follow-up	1		
Cottraux 1990	11/20	14/20		0.79 [0.48, 1.28]
Subtotal (95% CI)	11/20	14/20	<u>-</u>	0.79 [0.48, 1.28]
Test for heterogeneity: not a	pplicable		-	•
Test for overall effect: Z = 0	.97 (P = 0.33)			
03 ERP + Fluvoxamine v ERP	+ placebo: 1 year follow-up			
Cottraux 1990	11/20	12/20		0.92 [0.54, 1.56]
Subtotal (95% CI)	11/20	12/20		0.92 [0.54, 1.56]
Test for heterogeneity: not a	•	•	Ŧ	
Test for overall effect: $Z = 0$				
	•			
		0.1	1 0.2 0.5 1 2 5	10


Favours ERP+SRI Favours ERP


Favours ERP+SRI Favours ERP


Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP 07 Y-BOCS

Outcome:

ERP + SRI ERP SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP van Balkom 1998 12.60(6.60) 17.10(8.40) -0.58 [-1.24, 0.08] Subtotal (95% CI) 18 19 -0.58 [-1.24, 0.08] Test for heterogeneity: not applicable Test for overall effect: Z = 1.73 (P = 0.08) 02 MBT + Fluvoxamine v MBT + placebo -0.47 [-1.03, 0.10] -0.47 [-1.03, 0.10] Hohagen 1998 24 12.40(6.80) 25 15.90(7.90) Subtotal (95% CI) 25 24 Test for heterogeneity: not applicable Test for overall effect: Z = 1.61 (P = 0.11) 03 ERP + Clomipramine v ERP Foa 2005 19 10.50(8.20) 21 11.00(7.90) -0.06 [-0.68, 0.56] Subtotal (95% CI) 21 -0.06 [-0.68, 0.56] Test for heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85) Total (95% CI) 65 -0.37 [-0.72, -0.01] Test for heterogeneity: $Chi^2 = 1.46$, df = 2 (P = 0.48), $I^2 = 0\%$ Test for overall effect: Z = 2.04 (P = 0.04)







OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome: 22 Target rituals (assessor): time (follow-up) SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (6 months follow-up) Cottraux 1990 10.30(8.70) 12 11.90(9.70) -0.17 [-0.94, 0.60] 14 Subtotal (95% CI) 14 12 -0.17 [-0.94, 0.60] Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67) 02 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 12 9.70(9.90) 11 9.40(6.90) 0.03 [-0.78, 0.85] Subtotal (95% CI) 0.03 [-0.78, 0.85] 12 11 Test for heterogeneity: not applicable Test for overall effect: Z = 0.08 (P = 0.94) 0 2 Favours BT+SRI Favours BT Review: OCD: combination therapy Comparison: 01 ERP+ SRI v ERP 23 Target rituals (assessor): discomfort (post-treatment) Outcome: BT + SRI ВΤ SMD (fixed) SMD (fixed) or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (post treatment) Cottraux 1990 17.00(8.35) -0.80 [-1.54, -0.07] 10.25(8.04) Subtotal (95% CI) 15 -0.80 [-1.54, -0.07] Test for heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.03) 02 Exposure + Clomipramine v Exposure + placebo (at 7 weeks) Marks 1980 10 2.90(2.00) 10 4.90(1.80) -1.01 [-1.95, -0.06] Subtotal (95% CI) 10 10 -1.01 [-1.95, -0.06] Test for heterogeneity: not applicable Test for overall effect: Z = 2.09 (P = 0.04) Total (95% CI) -0.88 [-1.46, -0.30] 25 Test for heterogeneity: Chi² = 0.11, df = 1 (P = 0.74), l² = 0% Test for overall effect: Z = 2.97 (P = 0.003) Π Favours BT+SRI Favours BT Review: OCD: combination therapy 01 ERP+ SRI v ERP Comparison: 24 Target rituals (assessor): discomfort (follow-up) Outcome:

Study or sub-category	N	BT + SRI Mean (SD)	N	BT Mean (SD)		8	SMD (fixed) 95% CI		SMD (fixed) 95% Cl
01 ERP + Fluvoxamine v ER	RP + placebo (6 m	onths follow-up)							
Cottraux 1990	14	12.21(9.25)	12	13.30(9.80)			-		-0.11 [-0.88, 0.66]
Subtotal (95% CI)	14		12				•		-0.11 [-0.88, 0.66]
Test for heterogeneity: not	applicable						Ī		•
Test for overall effect: Z =	0.28 (P = 0.78)								
02 ERP + Fluvoxamine v ER	RP + placebo (1 ye	ear follow-up)							
Cottraux 1990	12	11.50(10.90)	11	11.00(9.10)			-		0.05 [-0.77, 0.87]
Subtotal (95% CI)	12		11				•		0.05 [-0.77, 0.87]
Test for heterogeneity: not	applicable						T		•
Test for overall effect: Z =	0.11 (P = 0.91)								
					-4	-2	-	2	4
						DT.	CDL F	NIVA DT	

OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP Outcome: 25 Target rituals (assessor): duration per day SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) N Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (post treatment) Cottraux 1990 3.93(2.26) 15 5.40(2.19) -0.64 [-1.37, 0.08] 16 Subtotal (95% CI) 15 -0.64 [-1.37, 0.08] Test for heterogeneity: not applicable Test for overall effect: Z = 1.74 (P = 0.08) 02 ERP + Fluvoxamine v ERP + placebo (6 months follow-up) Cottraux 1990 14 4.00(2.80) 12 4.67(2.27) -0.25 [-1.03, 0.52] Subtotal (95% CI) 14 12 -0.25 [-1.03, 0.52] Test for heterogeneity: not applicable Test for overall effect: Z = 0.64 (P = 0.52) 03 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 2.70(2.70) 11 3.30(2.70) -0.21 [-1.04, 0.61] 12 Subtotal (95% CI) -0.21 [-1.04, 0.61] Test for heterogeneity: not applicable Test for overall effect: Z = 0.51 (P = 0.61) Favours BT+SRI Favours BT OCD: combination therapy Review: Comparison: 01 ERP+ SRI v ERP 26 Behavioural avoidance test: discomfort (post treatment) Outcome SMD (fixed) ΒT SMD (fixed) Study BT + SRI Mean (SD) Mean (SD) 95% CI 95% CI or sub-category 01 ERP + Fluvoxamine v ERP + placebo (post treatment) Cottraux 1990 16 9.12(6.55) 15 15.61(7.61) -0.89 [-1.64, -0.15] Subtotal (95% CI) -0.89 [-1.64, -0.15] 16 15 Test for heterogeneity: not applicable Test for overall effect: Z = 2.35 (P = 0.02) 02 Exposure + Clomipramine v Exposure + placebo (at 7 weeks) 10 15.40(11.90) 10 16.90(10.00) -0.13 [-1.01, 0.75] Subtotal (95% CI) 10 -0.13 [-1.01, 0.75] Test for heterogeneity: not applicable Test for overall effect: Z = 0.29 (P = 0.77)Total (95% CI) 25 -0.57 [-1.14, -0.01] Test for heterogeneity: Chi² = 1.69, df = 1 (P = 0.19), l² = 40.7% Test for overall effect: Z = 1.98 (P = 0.05) Ó Favours BT+SRI Favours BT Review: OCD: combination therapy Comparison 01 ERP+ SRI v ERP Outcome: 27 Behavioural avoidance test: discomfort (follow-up) BT + SRI ВТ SMD (fixed) SMD (fixed) Study or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 ERP + Fluvoxamine v ERP + placebo (1 year follow-up) Cottraux 1990 10.20(9.20) 11.50(9.20) -0.14 [-0.96, 0.68] 12 11 Subtotal (95% CI) -0.14 [-0.96, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.33 (P = 0.74) Favours BT+SRI Favours BT Review: OCD: combination therapy Comparison: 02 ERP + Clomipramine v Clomipramine Outcome: 01 Leaving the study early Study BT + Clomipramine RR (fixed) RR (fixed) Clomipramine or sub-category n/Ν n/Ν 95% CL 95% CL Foa 2005 14/33 20/47 1.00 [0.59, 1.67] Total (95% CI) 1.00 [0.59, 1.67] 33 47 Total events: 14 (BT + Clomipramine), 20 (Clomipramine) Test for heterogeneity: not applicable Test for overall effect: Z = 0.01 (P = 0.99) 0.2 0.5 5 10

Favours BT+CMI Favours CMI

Review: OCD: combination therapy Comparison: Outcome: 03 Non-responders (CGI) Study or sub-category Foa 2005 Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 2.50 (P = 0.01) OCD: combination therapy Review 02 ERP + Clomipramine v Clomipramine Comparison: 05 Y-BOCS Outcome:

02 ERP + Clomipramine v Clomipramine

BT + Clomipramine Clomipramine RR (fixed) RR (fixed) 95% CI 95% CI nΝ n/N 12/33 32/47 0.53 [0.33, 0.87] 33 47 0.53 [0.33, 0.87] Total events: 12 (BT + Clomipramine), 32 (Clomipramine) 0.1 0.2 0.5 2 5 10

> Favours BT+CMI Favours CMI

> > Favours BT+CMI Favours CMI

Favours Anti-ERP+FLV

Study BT + Clomipramine Clomipramine SMD (fixed) SMD (fixed) N Ν or sub-category Mean (SD) Mean (SD) 95% CI 95% CI Foa 2005 10.50(8.20) 27 18.20(7.80) -0.95 [-1.57, -0.33] Total (95% CI) 19 27 -0.95 [-1.57, -0.33] Test for heterogeneity; not applicable Test for overall effect: Z = 3.00 (P = 0.003) ń

Review: OCD: combination therapy

Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine

01 Leaving the study early Outcome:

Study ERP+Fluvoxamine Anti-ERP+Fluvoxamine RR (fixed) RR (fixed) 95% CI 95% CI or sub-category n/N n/Ν Cottraux 1990 4/20 7/20 0.57 [0.20, 1.65] Total (95% CI) 4/20 7/20 0.57 [0.20, 1.65] Test for heterogeneity: not applicable Test for overall effect: Z = 1.03 (P = 0.30) 0.2 0.5 5

Favours ERP+FLV

Review: OCD: combination therapy

Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 02 Leaving the study early due to adverse effects Outcome:

Anti-ERP+Fluvoxamine RR (fixed) RR (fixed) Study ERP+Fluvoxamine or sub-category n/Ν n/Ν 95% CL 95% CL Cottraux 1990 2/20 2/20 1.00 [0.16, 6.42] Total (95% CI) 2/20 2/20 1.00 [0.16, 6.42] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) 0.1 0.2 0.5 2 5 10 Favours ERP+FLV Favours Anti-ERP+FLV

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

03 Global criterion of non-improvement (duration of rituals) Outcome:

Study or sub-category	ERP+Fluvoxamine n/N	Anti-ERP+Fluvoxamine RR (fixed) n/N 95% CI		RR (fixed) 95% Cl
01 Post-treatment				
Cottraux 1990	9/20	13/20		0.69 [0.39, 1.24]
Subtotal (95% CI)	9/20	13/20		0.69 [0.39, 1.24]
Test for heterogeneity: not a	pplicable		-	
Test for overall effect: $Z = 1$.24 (P = 0.22)			
02.6 months follow-up				
Cottraux 1990	11/20	15/20		0.73 [0.46, 1.17]
Subtotal (95% CI)	11/20	15/20	-	0.73 [0.46, 1.17]
Test for heterogeneity: not a	pplicable		-	
Test for overall effect: Z = 1	.29 (P = 0.20)			
03.1 year follow-up				
Cottraux 1990	11/20	14/20		0.79 [0.48, 1.28]
Subtotal (95% CI)	11/20	14/20		0.79 [0.48, 1.28]
Test for heterogeneity: not a	pplicable	-	-	
Test for overall effect: $Z = 0$				

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison:

Outcome: 04 Hamilton Depression Scale

Study or sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	-ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Cottraux 1990	16	9.12(6.03)	13	10.46(6.98)	<u> </u>	-0.20 [-0.94, 0.53]
Subtotal (95% CI)	16		13		→	-0.20 [-0.94, 0.53]
Test for heterogeneity: not applica	ble]	
Test for overall effect: $Z = 0.54$ (P	= 0.59)					
02 6 months follow-up						
Cottraux 1990	14	10.71(6.27)	11	11.27(6.02)	<u> </u>	-0.09 [-0.88, 0.70]
Subtotal (95% CI)	14		11		•	-0.09 [-0.88, 0.70]
Test for heterogeneity: not applica	ble				Ī	
Test for overall effect: $Z = 0.22$ (P	= 0.83)					
03.1 year follow-up						
Cottraux 1990	12	11.80(7.90)	10	8.50(3.80)	—	0.50 [-0.36, 1.35]
Subtotal (95% CI)	12		10			0.50 [-0.36, 1.35]
Test for heterogeneity: not applica	ble				*	
Test for overall effect: $Z = 1.14$ (P	= 0.25)					
					-10 -5 0 5	10

Favours ERP + FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 05 Target rituals (assessor): time Comparison:

Outcome:

Study or sub-category	N E	RP+Fluvoxamine Mean (SD)	Anti N	i-ERP+Fluvoxamine Mean (SD)			D (fixed) 15% Cl			SMD (fixed) 95% Cl
01 Post treatment										
Cottraux 1990	16	8.50(7.30)	13	12.84(7.78)		_	₩			-0.56 [-1.31, 0.19]
Subtotal (95% CI)	16		13							-0.56 [-1.31, 0.19]
Test for heterogeneity: not applica	able					_				
Test for overall effect: $Z = 1.47$ (F	P = 0.14)									
02.6 months follow-up										
Cottraux 1990	14	10.30(8.70)	11	13.50(3.11)		_	-			-0.45 [-1.25, 0.35]
Subtotal (95% CI)	14		11			-				-0.45 [-1.25, 0.35]
Test for heterogeneity: not applica	able									
Test for overall effect: $Z = 1.10$ (F	P = 0.27)									
03.1 year follow-up										
Cottraux 1990	12	9.70(9.90)	10	11.40(9.40)		_	_			-0.17 [-1.01, 0.67]
Subtotal (95% CI)	12		10				-			-0.17 [-1.01, 0.67]
Test for heterogeneity: not applica	able						1			
Test for overall effect: $Z = 0.39$ (F	P = 0.69)									
					-4	-2	ò	2	4	
					Favou	ırs ERP+FLV	/ Favo	ours Anti-E	RP+FLV	

Review: OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison: Outcome: 06 Target rituals (assessor): discomfort

N	Mean (SD)	N	Manager (CD)				
			Mean (SD)	95% CI	95% CI		
16	10.25(8.04)	13	11.30(10.27)	-	-0.11 [-0.84, 0.62]		
16		13		•	-0.11 [-0.84, 0.62]		
le				I			
0.76)							
14	12.21(9.25)	11	13.18(8.50)	— —	-0.11 [-0.90, 0.69]		
14		11		•	-0.11 [-0.90, 0.69]		
le				I	·		
0.79)							
12	11.50(10.90)	10	9.60(8.60)		0.18 [-0.66, 1.03]		
12		10			0.18 [-0.66, 1.03]		
le				T-			
0.67)							
	16 e 0.76) 14 14 e 0.79)	16 e 0.76) 14 12.21(9.25) 14 e 0.79) 12 11.50(10.90) 12 e	16	16	16		

Favours ERP+FLV Favours Anti-ERP+FLV

Review:

OCD: combination therapy
03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Comparison: Outcome: 07 Target rituals (assessor): duration per day

Study or sub-category	N Ef	RP+Fluvoxamine Mean (SD)	Anti- N	ERP+Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Post treatment						
Cottraux 1990	16	3.93(2.26)	13	4.07(2.56)	_ 	-0.06 [-0.79, 0.68]
Subtotal (95% CI)	16		13		•	-0.06 [-0.79, 0.68]
est for heterogeneity; not a	applicable				Ţ	
est for overall effect: Z = 0).15 (P = 0.88)					
12.6 months follow-up						
Cottraux 1990	14	4.00(2.80)	11	4.09(2.59)	 _	-0.03 [-0.82, 0.76]
Subtotal (95% CI)	14		11		•	-0.03 [-0.82, 0.76]
est for heterogeneity; not a	applicable				T	
est for overall effect: Z = 0).08 (P = 0.94)					
3.1 year follow-up						
Cottraux 1990	12	2.70(2.70)	10	3.20(3.10)		-0.17 [-1.01, 0.67]
Subtotal (95% CI)	12		10		-	-0.17 [-1.01, 0.67]
est for heterogeneity; not a	applicable				7	
est for overall effect: $Z = 0$).39 (P = 0.70)					

OCD: combination therapy

03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine 08 Behavioural avoidance test: discomfort Comparison: Outcome:

Study	E	RP+Fluvoxamine	Anti	i-ERP+Fluvoxamine		:	SMD (fixed)			SMD (fixed)
or sub-category	N	Mean (SD)	N	Mean (SD)			95% CI			95% CI
01 Post treatment										
Cottraux 1990	16	9.12(6.55)	13	11.46(6.75)			_			-0.34 [-1.08, 0.40]
Subtotal (95% CI)	16		13				-			-0.34 [-1.08, 0.40]
Test for heterogeneity: not a	applicable						- [
Test for overall effect: $Z = 0$	0.91 (P = 0.36)									
02.1 year follow-up										
Cottraux 1990	12	10.20(9.20)	10	10.30(9.40)			_			-0.01 [-0.85, 0.83]
Subtotal (95% CI)	12		10				-			-0.01 [-0.85, 0.83]
Test for heterogeneity: not a	applicable						[
Test for overall effect: $Z = 0$	0.02 (P = 0.98)									
					-4	-5	_	÷	4	

Favours ERP+FLV Favours Anti-ERP+FLV

Review: OCD: combination therapy Comparison: 03 ERP + Fluvoxamine v Anti-ERP + Fluvoxamine Outcome 09 Compulsive activity checklist SMD (fixed) SMD (fixed) Study ERP+Fluvoxamine Anti-ERP+Fluvoxamine or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Post treatment Cottraux 1990 14.56(17.38) 13 21.53(12.56) -0.44 [-1.18, 0.30] 16 Subtotal (95% CI) 16 13 -0.44 [-1.18, 0.30] Test for heterogeneity: not applicable Test for overall effect: Z = 1.16 (P = 0.25) 02.1 year follow-up Cottraux 1990 Subtotal (95% CI) 12 15.50(17.60) 10 20.70(14.30) -0.31 [-1.15, 0.54] 12 10 -0.31 [-1.15, 0.54] Test for heterogeneity; not applicable Test for overall effect: Z = 0.72 (P = 0.47) -2 0 Favours ERP+FLV Favours Anti-ERP+FLV OCD: combination therapy Review: 04 CT + Fluvoxamine v CT Comparison: 01 Leaving the study early Outcome: Study CT + Fluvoxamine CT RR (fixed) RR (fixed) or sub-category n/N 95% CI 95% CI n/N van Balkom 1998 10/24 1.74 [0.75, 4.03] 6/25 Total (95% CI) 10/24 6/25 1.74 [0.75, 4.03] Test for heterogeneity: not applicable Test for overall effect: Z = 1.28 (P = 0.20) 0.2 0.5 5 10 Favours CT+FLV Favours CT OCD: combination therapy Review: 04 CT + Fluvoxamine v CT Comparison: Outcome 02 Y-BOCS SMD (fixed) SMD (fixed) Study CT + Fluvoxamine CT or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 14 15.60(5.40) 19 13.50(9.70) 0.25 [-0.44, 0.94] Total (95% CI) 19 0.25 [-0.44, 0.94] Test for heterogeneity: not applicable Test for overall effect: Z = 0.71 (P = 0.48) -0.5 0.5 Ò Favours CT+FLV Favours CT Review: OCD: combination therapy 04 CT + Fluvoxamine v CT Comparison: 03 Padua Inventory Outcome: Study CT + Fluvoxamine CT SMD (fixed) SMD (fixed) Ν or sub-category Ν Mean (SD) Mean (SD) 95% CI 95% CI van Balkom 1998 14 43.50(18.40) 19 49.10(23.60) -0.25 [-0.95, 0.44] Total (95% CI) 19 -0.25 [-0.95, 0.44] Test for heterogeneity; not applicable Test for overall effect: Z = 0.72 (P = 0.47) -0.5 Ó 0.5 Favours CT+FLV Favours CT OCD: combination therapy Comparison: 04 CT + Fluvoxamine v CT Outcome 04 Beck Depression Inventory SMD (fixed) SMD (fixed) Study CT + Fluvoxamine CT or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 14 10.80(6.60) 19 9.90(7.00) 0.13 [-0.56, 0.82]

19

-0.5

Ó

Favours CT+FLV Favours CT

0.5

0.13 [-0.56, 0.82]

Total (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72)

OCD: combination therapy Review: Comparison: 04 CT + Fluvoxamine v C Outcome 05 Symptom Checklist-90 SMD (fixed) SMD (fixed) Study CT + Fluvoxamine CT or sub-category Ν Mean (SD) N Mean (SD) 95% CI 95% CI van Balkom 1998 162.00(42.70) 19 163.40(44.40) -0.03 [-0.72, 0.66] 14 Total (95% CI) -0.03 [-0.72, 0.66] Test for heterogeneity: not applicable Test for overall effect: Z = 0.09 (P = 0.93) -0.5 ò 0.5 Favours CT+FLV Favours CT OCD: combination therapy Review: Comparison: 04 CT + Fluvoxamine v CT Outcome 06 Anxiety Discomfort Scale: patient's ratings SMD (fixed) SMD (fixed) CT Study CT + Fluvoxamine Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category van Balkom 1998 13.00(4.90) 19 12.50(9.30) 0.06 [-0.63, 0.75] Total (95% CI) 19 0.06 [-0.63] 0.751 Test for heterogeneity: not applicable Test for overall effect: Z = 0.18 (P = 0.86) -0.5 0.5 Ó Favours CT+FLV Favours CT Review: OCD: combination therapy Comparison: 04 CT + Fluvoxamine v CT 07 Anxiety Discomfort Scale: therapist's ratings Outcome Study CT + Fluvoxamine CT SMD (fixed) SMD (fixed) Ν Ν Mean (SD) or sub-category Mean (SD) 95% CI 95% CI van Balkom 1998 14 13.60(7.50) 19 13.10(10.20) 0.05 [-0.64, 0.74] Total (95% CI) 19 0.05 [-0.64, 0.74] Test for heterogeneity; not applicable Test for overall effect: Z = 0.15 (P = 0.88) -0.5 Ó 0.5 Favours CT+FLV Favours CT Review: OCD: combination therapy Comparison: 04 CT + Fluvoxamine v CT Outcome 08 Anxiety Discomfort Scale: assessor's ratings SMD (fixed) Study + Fluvoxamine CT SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 14 13.80(4.70) 19 12.50(9.50) 0.16 [-0.53, 0.85] Total (95% CI) 19 0.16 [-0.53, 0.85] Test for heterogeneity: not applicable Test for overall effect: Z = 0.46 (P = 0.65) -0.5 0.5 Ó Favours CT+FLV Favours CT Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome: 01 Leaving the study early RR (fixed) RR (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine 95% CI 95% CI or sub-category n/N n/N van Balkom 1998 10/28 10/24 0.86 [0.43, 1.70] Total (95% CI) 10/24 0.86 [0.43, 1.70] 10/28 Test for heterogeneity: not applicable Test for overall effect: Z = 0.44 (P = 0.66) 0.1 0.2 0.5 5 10 Favours ERP+FLV Favours CT+FLV OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine 02 Y-BOCS Outcome Study ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) M Mean (SD) 95% CI 95% CI van Balkom 1998 18 12.60(6.60) 15.60(5.40) -0.48 [-1.19, 0.23] 14 Total (95% CI) 14 -0.48 [-1.19, 0.23] Test for heterogeneity: not applicable Test for overall effect: Z = 1.32 (P = 0.19)

-2

Ó Favours ERP+FLV Favours CT+FLV

Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome 03 Padua Inventory SMD (fixed) SMD (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine or sub-category N Mean (SD) N Mean (SD) 95% CI 95% CI van Balkom 1998 18 43.20(23.50) 43.50(18.40) -0.01 [-0.71. 0.68] 14 Total (95% CI) -0.01 [-0.71, 0.68] Test for heterogeneity: not applicable Test for overall effect: Z = 0.04 (P = 0.97) -0.5 ò 0.5 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison: Outcome 04 Beck Depression Inventory SMD (fixed) SMD (fixed) Study ERP + Fluvoxamine CT + Fluvoxamine Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category 18 van Balkom 1998 10.10(7.20) 14 10.80(6.60) -0.10 [-0.80, 0.60] Total (95% CI) 14 -0.10 [-0.80, 0.60] 18 Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) -0.5 0.5 Ó Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 FRP + Fluvoxamine v CT + Fluvoxamine Comparison: 05 Symptom Checklist-90 Outcome Study ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) Ν or sub-category Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 18 154.50(51.40) 14 162.00(42.70) -0.15 [-0.85, 0.55] Total (95% CI) 18 14 -0.15 [-0.85, 0.55] Test for heterogeneity; not applicable Test for overall effect: Z = 0.43 (P = 0.67) -0.5 Ó 0.5 Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy Comparison: 05 ERP + Fluvoxamine v CT + Fluvoxamine Outcome 06 Anxiety Discomfort Scale: patient's ratings Study + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 18 13.00(4.90) 14 13.00(4.90) 0.00 [-0.70, 0.70] Total (95% CI) 14 0.00 [-0.70, 0.70] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) -0.5 0.5 Ó Favours ERP+FLV Favours CT+FLV OCD: combination therapy Review: 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison: Outcome 07 Anxiety Discomfort Scale: therapist's ratings SMD (fixed) SMD (fixed) Study + Fluvoxamine CT + Fluvoxamine Ν Ν 95% CI or sub-category Mean (SD) Mean (SD) 95% CI van Balkom 1998 18 14.20(10.30) 14 13.60(7.50) 0.06 [-0.64, 0.76] Total (95% CI) 14 0.06 [-0.64] 0.761 18 Test for heterogeneity: not applicable Test for overall effect: Z = 0.18 (P = 0.86) -0.5 0.5 Ó Favours ERP+FLV Favours CT+FLV Review: OCD: combination therapy 05 ERP + Fluvoxamine v CT + Fluvoxamine Comparison: Outcome 08 Anxiety Discomfort Scale: assessor's ratings ERP + Fluvoxamine CT + Fluvoxamine SMD (fixed) SMD (fixed) Study or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI van Balkom 1998 14.20(8.70) 13.80(4.70) 0.05 [-0.64, 0.75] 18 14 Total (95% CI) 18 14 0.05 [-0.64, 0.75] Test for heterogeneity: not applicable Test for overall effect: Z = 0.15 (P = 0.88)

-0.5

Ó

Favours ERP+FLV Favours CT+FLV

0.5

Review: OCD: combination therapy

06 Children: ERP + Fluvoxamine v Fluvoxamine alone Comparison: 01 Non-responder (Y-BOCS reliable change) Outcome:

ERP + Fluvoxamine n/N	Fluvoxamine n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl			
0/5	3/5		0.14 [0.01, 2.21]			
0/5	3/5		0.14 [0.01, 2.21]			
icable		-	•			
(P = 0.16)						
0/5	2/5		0.20 [0.01, 3.35]			
0/5	2/5		0.20 [0.01, 3.35]			
icable						
(P = 0.26)						
0/5	2/5		0.20 [0.01, 3.35]			
0/5	2/5		0.20 [0.01, 3.35]			
icable			- ,			
(P = 0.26)						
i	0/5 0/5 icable (P = 0.16) 0/5 0/5 icable (P = 0.26)	n/N n/N 0/5 3/5 0/5 3/5 icable (P = 0.16) 0/5 2/5 0/5 2/5 icable (P = 0.26) 0/5 2/5 icable (P = 0.26)	n/N n/N 95% Cl 0/5 3/5 0/5 3/5 icable (P = 0.16) 0/5 2/5 0/5 2/5 icable (P = 0.26)			

Favours ERP+FLV Favours FLV

OCD: combination therapy Review:

Comparison: 06 Children: ERP + Fluvoxamine v Fluvoxamine alone

Outcome: 02 CY-BOCS

Study or sub-category	ERP + Fluvoxamine N Mean (SD)		N	Fluvoxamine Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 At 43 weeks					_	
Neziroglu 2000	5	-11.60(5.64)	5	-3.60(4.28)		-1.44 [-2.93, 0.04]
Subtotal (95% CI)	5		5			-1.44 [-2.93, 0.04]
Test for heterogeneity: not applicab Test for overall effect: Z = 1.91 (P =						
02 At 52 weeks Neziroglu 2000	5	-14.00(6.08)	5	-3.40(6.69)	_	1 50 1 2 00 0 001
Subtotal (95% CI)	5	-14.00(6.00)	5	-3.40(6.69)		-1.50 [-3.00, 0.00] -1.50 [-3.00, 0.00]
Fest for heterogeneity: not applicab	د ما		•			-1.30 [-3.00, 0.00]
Test for overall effect: Z = 1.96 (P =						
03 At 2 years						
Neziroglu 2000	5	-20.20(2.17)	5	-9.00(11.42)		-1.23 [-2.65, 0.19]
Subtotal (95% CI)	- 5		5			-1.23 [-2.65, 0.19]
Test for heterogeneity: not applicab	ile					
Test for overall effect: $Z = 1.70$ (P =	= 0.09)					
					-4 -2 0 2	4

Favours ERP+FLV Favours FLV OCD: combination therapy

Review:

06 Children: ERP + Fluvoxamine v Fluvoxamine alone 03 NIMH-GOCS Comparison:

Outcome:

Study or sub-category	EF N	RP + Fluvoxamine Mean (SD)	N	Fluvoxamine Mean (SD)			SMD (fixed) 95% Cl			SMD (fixed) 95% CI
D1 At 43 weeks										
Neziroglu 2000	5	-4.00(1.58)	5	-2.80(2.39)			-			-0.54 [-1.81, 0.74]
Subtotal (95% CI)	5		5				-			-0.54 [-1.81, 0.74]
est for heterogeneity: not applicabl	le						٦			,
est for overall effect: Z = 0.82 (P =										
12 At 52 weeks										
Neziroglu 2000	5	-3.80(2.17)	5	-2.20(2.39)			_			-0.63 [-1.92, 0.66]
ubtotal (95% CI)	5		5				-			-0.63 [-1.92, 0.66]
est for heterogeneity: not applicabl	le						٦			
est for overall effect: Z = 0.96 (P =										
3 At 2 years										
Neziroglu 2000	5	-7.40(2.88)	5	-4.00(4.53)			-			-0.81 [-2.13, 0.51]
ubtotal (95% CI)	5		5				-			-0.81 [-2.13, 0.51]
est for heterogeneity: not applicabl	le						_			,
est for overall effect: Z = 1.20 (P =										
					-10	-5	ó	5	10	
					Favou	urs ERP+	FLV Favour	s FLV		

OCD: combination therapy Review: 07 Children: CBT + Sertraline v Sertraline Comparison: Outcome: 01 Leaving the study early CBT + Sertraline Sertraline RR (fixed) RR (fixed) Study 95% CI or sub-category n/N n/Ν 95% CI POTS 2004 1.00 [0.22, 4.54] 3/28 3/28 Total (95% CI) 3/28 3/28 1.00 [0.22, 4.54] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) 0.1 0.2 0.5 5 10 Favours CBT+Sertrali Favours Sertraline Review: OCD: combination therapy Comparison: 07 Children: CBT + Sertraline v Sertraline Outcome: 02 Leaving the study early due to adverse events RR (fixed) RR (fixed) Study CBT + Sertraline Sertraline or sub-category n/Ν n/N 95% CI 95% CI POTS 2004 1/28 1/28 1.00 [0.07, 15.21] Total (95% CI) 1/28 1/28 1.00 [0.07, 15.21] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00)0.1 0.2 0.5 ż 5 10 Favours CBT+Sertrali Favours Sertraline Review: OCD: combination therapy Comparison: 07 Children: CBT + Sertraline v Sertraline 03 CY-BOCS Outcome CBT + Sertraline Sertraline SMD (fixed) SMD (fixed) or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CL POTS 2004 11.20(8.60) 28 16.50(9.10) -0.59 [-1.13, -0.05] 28 Total (95% CI) 28 28 -0.59 [-1.13, -0.05] Test for heterogeneity; not applicable Test for overall effect: Z = 2.16 (P = 0.03) -0.5 Ó 0.5 Favours CBT+Sertrali Favours Sertraline Review: OCD: combination therapy Comparison: 08 Children: CBT + Sertraline v CBT Outcome: 01 Leaving the study early Study CBT + Sertraline Sertraline RR (fixed) RR (fixed) 95% CI 95% CI n/N n/N or sub-category POTS 2004 1.00 [0.22, 4.54] 3/28 3/28 Total (95% CI) 3/28 3/28 1.00 [0.22, 4.54] Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) 0.1 0.2 0.5 2 5 10 Favours CBT+Sertrali Favours Sertraline Review: OCD: combination therapy 08 Children: CBT + Sertraline v CBT Comparison: Outcome 02 CY-BOCS

Study CBT + Sertraline Sertraline SMD (fixed) SMD (fixed) Ν Mean (SD) Ν or sub-category Mean (SD) 95% CI 95% CI POTS 2004 28 11.20(8.60) 28 14.00(9.50) -0.30 [-0.83, 0.22] Total (95% CI) 28 28 -0.30 [-0.83, 0.22] Test for heterogeneity; not applicable Test for overall effect: Z = 1.13 (P = 0.26)

> ń Favours CBT+Sertrali Favours Sertraline

0.5

-0.5

Other medical interventions Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cinquiotomy 01 CPRS @ 3 months; change score Outcome Cingulotomy SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI Fodstad 1982 -5.75(1.06) 2 -13.75(0.35) 2 -5.79 [-38.62, 27.03] Total (95% CI) 2 -5.79 [-38.62, 27.03] Test for heterogeneity: not applicable Test for overall effect: Z = 0.35 (P = 0.73) -100 -50 Ó 50 100 Favours capsulotomy Favours cingulatomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy Outcome 02 CPRS @ 6 months: change score SMD (fixed) SMD (fixed) Cinquiotomy Study Capsulotomy or sub-category Mean (SD) Mean (SD) 95% CI 95% CI Fodstad 1982 2 -13.25(5.30) 2 -11.25(1.06) -0.30 [-2.89, 2.29] Total (95% CI) -0.30 [-2.89, 2.29] Test for heterogeneity: not applicable Test for overall effect: Z = 0.23 (P = 0.82) Ó Favours capsulotomy Favours cingulatomy Review: OCD: other medical 01 Stereotactic anterior capsulotomy vs cinquiotomy Comparison: 03 CPRS @ 12 months: change score Outcome Study Capsulotomy Cingulotomy SMD (fixed) SMD (fixed) Ν Ν or sub-category Mean (SD) Mean (SD) 95% CI 95% CL Fodstad 1982 2 -13.50(2.83) -17.25(6.01) 0.46 [-2.78, 3.70] 2 Total (95% CI) 2 0.46 [-2.78, 3.70] Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) -2 Ò ż Favours cinquiotomy Favours capsulotomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy 04 HAM-D @ 3 months: change score Outcome Capsulotomy SMD (fixed) SMD (fixed) Cingulotomy or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Fodstad 1982 -3.00(4.24) 2 2 -4.00(0.01) 0.19 [-2.05. 2.43] Total (95% CI) 2 0.19 [-2.05, 2.43] Test for heterogeneity: not applicable Test for overall effect: Z = 0.17 (P = 0.87) Ó -4 -2 Favours capsulotomy Favours cingulatomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy Outcome 05 HAM-D @ 6 months: change score SMD (fixed) SMD (fixed) Study Capsulotomy Cinquiotomy Mean (SD) N Mean (SD) 95% CI 95% CI or sub-category Fodstad 1982 2 -2.00(5.66) 2 -2.00(2.83) 0.00 [-1.96, 1.96] 0.00 [-1.96, 1.96] Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.00 (P = 1.00) Ó Favours capsulotomy Favours cingulatomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy 06 HAM-D @ 12 months: change score Outcome SMD (fixed) Capsulotomy Cingulotomy SMD (fixed) or sub-category M Mean (SD) M Mean (SD) 95% CI 95% CL Fodstad 1982 2 -1.50(4.95) -4.50(0.71) 0.48 [-2.89, 3.86]

2

0.48 [-2.89, 3.86]

Ó

Favours capsulotomy

Favours cingulatomy

Total (95% CI)

Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78)

OCD: other medical Review: Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy Outcome 07 HAM-A @ 3 months; change score SMD (fixed) SMD (fixed) Study Cingulotomy or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Fodstad 1982 2 -4.00(1.41) 2 -11.50(12.02) 0.50 [-2.94, 3.95] 0.50 [-2.94, 3.95] Total (95% CI) Test for heterogeneity: not applicable Test for overall effect: Z = 0.28 (P = 0.78) ò Favours capsulotomy Favours cingulatomy OCD: other medical Review: Comparison: 01 Stereotactic anterior capsulotomy vs cingulotomy 08 HAM-A @ 6 months; change score Outcome SMD (fixed) SMD (fixed) Study Capsulotomy Cinquiotomy Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category Fodstad 1982 2 -3.00(2.83) 2 -6.00(5.66) 0.38 [-2.54, 3.31] Total (95% CI) 2 0.38 [-2.54] 3.311 Test for heterogeneity: not applicable Test for overall effect: Z = 0.26 (P = 0.80) -2 Ó Favours cingulatomy Favours capsulotomy Review: OCD: other medical Comparison: 01 Stereotactic anterior capsulotomy vs cinquiotomy 09 HAM-A @ 12 months: change score Outcome: Capsulotomy Study Cingulotomy SMD (fixed) SMD (fixed) Ν Ν Mean (SD) or sub-category Mean (SD) 95% CI 95% CI Fodstad 1982 2 -2.50(3.54) -7.50(7.78) 0.47 [-2.84, 3.79] Total (95% CI) 2 0.47 [-2.84, 3.79] Test for heterogeneity; not applicable Test for overall effect: Z = 0.28 (P = 0.78) -2 ń Favours capsulotomy Favours cingulatomy Review: OCD: other medical 02 Repetitive transcranial magnetic stimulation; active vs placebo Comparison: Outcome: 01 Adverse effects Study Active RTMS Placebo RTMS RR (fixed) RR (fixed) 95% CI 95% CI or sub-category n/N n/Ν Alonso 2001 1/10 0/8 2.45 [0.11, 53.25] Total (95% CI) 10 8 2.45 [0.11, 53.25] Total events: 1 (Active RTMS), 0 (Placebo RTMS) Test for heterogeneity: not applicable Test for overall effect: Z = 0.57 (P = 0.57) 0.01 0.1 100 10 Favours active RTMS Favours placebo RTMS Review: OCD: other medical Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo Outcome: 02 Non-responders (Y-BOCS 40%) Study Active RTMS Placebo RTMS RR (fixed) RR (fixed) or sub-category n/Ν n/Ν 95% CI 95% CI Alonso 2001 8/10 7/8 0.91 [0.61, 1.37] Total (95% CD 10 8 0.91 [0.61, 1.37] Total events: 8 (Active RTMS), 7 (Placebo RTMS) Test for heterogeneity: not applicable Test for overall effect: Z = 0.43 (P = 0.67)


0.7

Favours active RTMS

1.5

Favours placebo RTMS


Review: OCD: other medical Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo Outcome 03 Y-BOCS: change score SMD (fixed) SMD (fixed) Study Active RTMS Placebo RTMS or sub-category N Mean (SD) Ν Mean (SD) 95% CI 95% CI Alonso 2001 10 -3.40(8.24) 8 -0.25(3.92) -0.45 [-1.39. 0.50] Total (95% CI) -0.45 [-1.39, 0.50] Test for heterogeneity: not applicable Test for overall effect; Z = 0.93 (P = 0.35) ò Favours active RTMS Favours placebo RTMS OCD: other medical Review: Comparison: 02 Repetitive transcranial magnetic stimulation; active vs placebo Outcome 04 HAM-D: change score Active RTMS Placebo RTMS SMD (fixed) SMD (fixed) Study Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI or sub-category Alonso 2001 10 -0.30(3.95) 8 0.25(1.16) -0.17 [-1.10, 0.76] Total (95% CI) -0.17 [-1.10, 0.76] 10 Test for heterogeneity: not applicable Test for overall effect: Z = 0.36 (P = 0.72) -2 0 Favours active RTMS Favours placebo RTMS Review: OCD: other medical 03 Repetitive transcranial magnetic stimulation; right vs left Comparison: 01 Y-BOCS @ post-treatment Outcome Study Right Left SMD (fixed) SMD (fixed) Ν Mean (SD) Ν Mean (SD) or sub-category 95% CI 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 17.00(4.86) 16.67(12.31) 0.03 [-1.10, 1.16] Subtotal (95% CI) 0.03 [-1.10, 1.16] Test for heterogeneity; not applicable Test for overall effect: Z = 0.06 (P = 0.96) -4 -2 ń Favours right Favours left Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left Outcome 02 BDI @ post-treatment Study Right Left SMD (fixed) SMD (fixed) or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 0.48 [-0.67, 1.64] 14.17(8.91) 6 9.67(8.26) Subtotal (95% CI) 0.48 [-0.67, 1.64] Test for heterogeneity: not applicable Test for overall effect: Z = 0.82 (P = 0.41) Favours right Favours left OCD: other medical Review: 03 Repetitive transcranial magnetic stimulation; right vs left Comparison: Outcome 03 MADRS @ post-treatment SMD (fixed) SMD (fixed) Study Right Left Mean (SD) N Mean (SD) 95% CI 95% CI or sub-category Ν 01 Right prefrontal v Left prefrontal Sachdey 2001 15.33(10.35) 6 6.00(7.51) 0.95 [-0.27, 2.18] Subtotal (95% CI) 0.95 [-0.27, 2.18] Test for heterogeneity: not applicable Test for overall effect: Z = 1.53 (P = 0.13) 0 Favours right Favours left Review: OCD: other medical Comparison: 03 Repetitive transcranial magnetic stimulation; right vs left 04 STAI-S @ post-treatment Outcome SMD (fixed) SMD (fixed) Left or sub-category Ν Mean (SD) Ν Mean (SD) 95% CI 95% CI 01 Right prefrontal v Left prefrontal Sachdev 2001 45.50(9.67) 45.00(15.02) 0.04 [-1.10, 1.17] Subtotal (95% Ch 0.04 [-1.10, 1.17] Test for heterogeneity; not applicable Test for overall effect: Z = 0.06 (P = 0.95) _4 -2 Ó ż à Favours right Favours left



Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 01 Adverse effects



Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 02 Leaving study early

Study or sub-category	Treatment 1 n/N	Treatment 2 n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
O1 Plasma exchange vs placebo)			
Perlmutter 1999	0/10	0/10		Not estimable
Subtotal (95% CI)	0	0		Not estimable
Total events: 0 (Treatment 1), 0	(Treatment 2)			
Test for heterogeneity: not appli	cable			
Test for overall effect: not applic	cable			
02 IV immunoglobulin vs placebo)			
Perlmutter 1999	1/10	0/10		— 3.00 [0.14, 65.90]
Subtotal (95% CI)	10	10		3.00 [0.14, 65.90]
Fotal events: 1 (Treatment 1), 0	(Treatment 2)		_	
Test for heterogeneity: not appli	cable			
Test for overall effect: Z = 0.70	(P = 0.49)			
03 Plasma exchange vs IV immu	ınoglobulin			
Perlmutter 1999	0/10	1/10		0.33 [0.02, 7.32]
Subtotal (95% CI)	10	10		0.33 [0.02, 7.32]
Fotal events: 0 (Treatment 1), 1	(Treatment 2)		_	
Test for heterogeneity: not appli	cable			
Test for overall effect: Z = 0.70	(P = 0.49)			
		0.01	0.1 1 10	100

Favours Treatment 1 Favours Treatment 2

Review: OCD: other medical

04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 03 Y-BOCS* Comparison:

Outcome:

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl	
01 Plasma exchange vs placebo	,						
Perlmutter 1999	5	18.20(6.10)	7	29.71(3.55)		-2.24 [-3.83, -0.66]	
Subtotal (95% CI)	5		7			-2.24 [-3.83, -0.66]	
Fest for heterogeneity: not appli	cable					·	
Test for overall effect: $Z = 2.77$	(P = 0.006)						
02 IV immunoglobulin vs placebo	,						
Perlmutter 1999	6	17.83(9.68)	7	29.71(3.55)		-1.57 [-2.88, -0.26]	
Subtotal (95% CI)	6		7		-	-1.57 [-2.88, -0.26]	
Fest for heterogeneity: not appli	cable				_		
Test for overall effect: $Z = 2.35$	(P = 0.02)						
03 Plasma exchange vs IV immu	ınoglobulin						
Perlmutter 1999	5	18.20(6.10)	6	17.83(9.68)	 _	0.04 [-1.15, 1.23]	
Subtotal (95% CI)	5		6			0.04 [-1.15, 1.23]	
Test for heterogeneity: not appli	cable				T		
Test for overall effect: $Z = 0.07$	(P = 0.95)						

Favours Treatment 1 Favours Treatment 2

OCD: other medical Review:

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 04 NIMH-Global Severity*

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl		
	ebo							
Perlmutter 1999	5	6.33(2.30)	7	8.29(0.76)		-1.15 [-2.43, 0.13]		
Subtotal (95% CI)	5		7		-	-1.15 [-2.43, 0.13]		
Test for heterogeneity: not ap	plicable							
Test for overall effect: $Z = 1$.								
02 IV immunoglobulin vs place	ebo							
Perlmutter 1999	6	6.33(1.97)	7	8.29(0.76)		-1.26 [-2.50, -0.03]		
Subtotal (95% CI)	6		7		-	-1.26 [-2.50, -0.03]		
est for heterogeneity; not ap	plicable							
est for overall effect: $Z = 2.0$	00 (P = 0.04)							
03 Plasma exchange vs IV im	munoglobulin							
Perlmutter 1999	5	6.33(2.30)	6	6.33(1.97)		0.00 [-1.19, 1.19]		
Subtotal (95% CI)	5		6	•	-	0.00 [-1.19, 1.19]		
Test for heterogeneity: not ap	plicable				T-			
rest for overall effect: Z = 0.								

Favours Treatment 1 Favours Treatment 2 OCD: other medical

Comparison: Outcome: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 05 CGI-Symptom Severity*

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)		S	SMD (fixed) 95% CI			SMD (fixed) 95% Cl
	0									
Perlmutter 1999	5	3.60(1.14)	7	4.86(0.48)		_				-1.43 [-2.78, -0.09]
Subtotal (95% CI)	5		7			-				-1.43 [-2.78, -0.09]
Test for heterogeneity: not appi	licable									
Test for overall effect: $Z = 2.09$	(P = 0.04)									
02 IV immunoglobulin vs placeb	0									
Perlmutter 1999	6	3.92(1.11)	7	4.86(0.48)		_	-			-1.06 [-2.25, 0.14]
Subtotal (95% CI)	6		7							-1.06 [-2.25, 0.14]
Test for heterogeneity: not appi	licable					_				
Test for overall effect: $Z = 1.73$	(P = 0.08)									
03 Plasma exchange vs IV imm	unoglobulin									
Perlmutter 1999	5	3.60(1.14)	6	3.92(1.11)		_	_			-0.26 [-1.45, 0.93]
Subtotal (95% CI)	5		6							-0.26 [-1.45, 0.93]
Test for heterogeneity: not appl	licable						_			·
Test for overall effect: Z = 0.43	(P = 0.67)									
					-4	-2	ó	2	4	
					Favours	s Treatmer	nt1 Favo	ours Treatr	nent 2	

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 06 Global Assessment Scale*

Study or sub-category	N	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% CI		
	ebo							
Perlmutter 1999	5	-63.40(12.36)	7	-54.86(4.30)		-0.93 [-2.16, 0.31]		
Subtotal (95% CI)	5		7			-0.93 [-2.16, 0.31]		
Test for heterogeneity: not ap	plicable							
Test for overall effect: $Z = 1.4$	17 (P = 0.14)							
02 IV immunoglobulin vs place	ebo							
Perlmutter 1999	6	-62.83(10.69)	7	-54.86(4.30)		-0.94 [-2.11, 0.23]		
Subtotal (95% CI)	6		7			-0.94 [-2.11, 0.23]		
Test for heterogeneity: not ap	plicable				_			
Test for overall effect: $Z = 1.5$	57 (P = 0.12)							
03 Plasma exchange vs IV imi	munoglobulin							
Perlmutter 1999	5	-63.40(12.36)	6	-62.83(10.69)	 _	-0.05 [-1.23, 1.14]		
Subtotal (95% CI)	5		6		-	-0.05 [-1.23, 1.14]		
Test for heterogeneity: not ap	plicable				T			
Test for overall effect: Z = 0.0								

Favours Treatment 1 Favours Treatment 2

OCD: other medical Review:

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome:

Study or sub-category N	1	Treatment 1 Mean (SD)	N	Treatment 2 Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Plasma exchange vs placebo						
Perlmutter 1999	5	4.20(2.28)	7	7.00(1.41)		-1.43 [-2.77, -0.09]
Subtotal (95% CI)	5		7			-1.43 [-2.77, -0.09]
Test for heterogeneity: not applicable						
Test for overall effect: Z = 2.09 (P = 0						
02 IV immunoglobulin vs placebo						
Perlmutter 1999	6	5.33(1.37)	7	7.00(1.41)		-1.12 [-2.32, 0.09]
Subtotal (95% CI)	6		7			-1.12 [-2.32, 0.09]
Test for heterogeneity: not applicable					-	
Test for overall effect: $Z = 1.81$ (P = 0	0.07)					
03 Plasma exchange vs IV immunoglo	bulin					
Perlmutter 1999	5	4.20(2.28)	6	5.33(1.37)		-0.56 [-1.79, 0.66]
Subtotal (95% CI)	5		6			-0.56 [-1.79, 0.66]
Test for heterogeneity: not applicable						•
Test for overall effect: $Z = 0.90$ (P = 0						
·						- ;
					-4 -2 0 2	4

Favours Treatment 1 Favours Treatment 2 OCD: other medical

Comparison: Outcome: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment) 08 NIMH-Depression*


itudy r sub-category	N	Treatment 1 N Mean (SD)		Treatment 2 Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl	
1 Plasma exchange vs place	bo						
Perlmutter 1999	5	3.60(2.19)	7	7.57(2.30)		-1.62 [-3.02, -0.23]	
ubtotal (95% CI)	5		7			-1.62 [-3.02, -0.23]	
est for heterogeneity; not ap	plicable						
est for overall effect: Z = 2.2							
12 IV immunoglobulin vs place	:bo						
Perlmutter 1999	6	4.83(2.14)	7	7.57(2.30)		-1.14 [-2.35, 0.07]	
ubtotal (95% CI)	6		7			-1.14 [-2.35, 0.07]	
est for heterogeneity: not ap	plicable						
est for overall effect: Z = 1.8							
3 Plasma exchange vs IV imi	munoalobulin						
Perlmutter 1999	5	3.62(0.19)	6	4.83(2.14)		-0.69 [-1.93, 0.55]	
Subtotal (95% CI)	5		6	•		-0.69 [-1.93, 0.55]	
est for heterogeneity: not ap	plicable						
est for overall effect: Z = 1.0	•						
	,/				4 -2 0 2		

Favours Treatment 1 Favours Treatment 2

Review: OCD: other medical

Comparison: 04 Plasma exchange vs IV immunoglobulin vs placebo (child/adolescent: at 1 month after start of treatment)

Outcome: 09 NIMH-OC*



Favours Treatment 1 Favours Treatment 2

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 01 Leaving study early

Study or sub-category	Plasma exchange n/N	IV immunoglobulin n/N	RR (fixed) 95% Cl	RR (fixed) 95% Cl
Perlmutter 1999	2/10	0/9		4.55 [0.25, 83.70]
Total (95% CI) Total events: 2 (Plasma ex Test for heterogeneity: not Test for overall effect: Z =	• •	9	-	4.55 [0.25, 83.70]
		0.0	1 0.1 1 10 10	00

Favours plasma exch. Favours IV immu.

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)

Outcome: 02 Y-BOCS*

Study or sub-category	N F	Plasma exchange Mean (SD)	N IV	' immunoglobulin Mean (SD)			MD (fixed) 95% Cl			SMD (fixed) 95% CI
Perlmutter 1999	5	10.50(8.27)	6	12.00(2.45)			-		-(0.24 [-1.43, 0.96]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 0			6			-	-		-(0.24 [-1.43, 0.96]
					-4	-2	ó	2	4	

Favours plasma exch. Favours IV immu.

Review: OCD: other medical

Comparison: 05 Plasma exchange vs IV immunoglobulin (child/adolescent: at 1 year after start of treatment)
Outcome: 03 Global Assessment Scale*

Study or sub-category	N F	Plasma exchange Mean (SD)	N I	V immunoglobulin Mean (SD)		SMD (fixed) 95% Cl				SMD (fixed) 95% Cl
Perlmutter 1999	5	-81.75(15.88)	6	-70.00(5.48)		-	+			-0.95 [-2.23, 0.34]
Total (95% CI) Test for heterogeneity: not a Test for overall effect: Z = 1			6							-0.95 [-2.23, 0.34]
					-4	-2	-	2	4	
					Favours plasma exch. Favours IV immu.					